NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • HBM Biopharma Summit
    22 - 24 September 2024,
    Zurich

    download

  • 24th Annual Biotech in Europe Forum
    25 - 26 September,
    Zurich

    download

  • Scale 100 Forum – EIC Scaling Club
    21 - 22 October 2024,
    Athens

    download
Inbiomotion and SPA – Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test® in Italy<
09 Oct 2024

Inbiomotion and SPA – Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test® in Italy

MAF Test® could increase the survival of 80% of the 55,000 early-stage breast cancer patients diagnosed each year.
Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)<
08 Oct 2024

Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)

The Phase I/II ADCElerate-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS
Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer<
01 Oct 2024

Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension<
25 Sep 2024

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

On track to announce topline data in Q1 2025

SparingVision Reports Progress on SPVN06 at Major Ophthalmology Conferences<
23 Sep 2024

SparingVision Reports Progress on SPVN06 at Major Ophthalmology Conferences

SPVN06 demonstrates continued favorable safety profile
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia<
18 Sep 2024

Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia

The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma<
12 Sep 2024

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate<
10 Sep 2024

Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate

This award highlights the promise of regenerative medicine technology, including Neurona’s pipeline of cell therapy candidates for patients with epilepsy and other CNS diseases.
Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor<
20 Aug 2024

Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor

Adcendo will obtain the exclusive development and commercialization rights for the asset globally, except for the Greater China region.
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update<
13 Aug 2024

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.